These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8286745)

  • 21. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
    Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
    Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
    Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
    Blakey DC; Watson GJ; Knowles PP; Thorpe PE
    Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
    Ghetie MA; Uhr JW; Vitetta ES
    Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of CD25+ and CD25-T cells in acute HIV infection in vitro.
    Ramilo O; Bell KD; Uhr JW; Vitetta ES
    J Immunol; 1993 Jun; 150(11):5202-8. PubMed ID: 8496611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental therapy in Hodgkin's disease.
    Engert A; Pohl C; Diehl V
    Ann Oncol; 1992 Sep; 3 Suppl 4():97-100. PubMed ID: 1333274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice.
    Clinchy B; Vitetta ES
    J Immunol Methods; 1998 Sep; 218(1-2):141-53. PubMed ID: 9819131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
    Kapp U; Wolf J; von Kalle C; Tawadros S; Röttgen A; Engert A; Fonatsch C; Stein H; Diehl V
    Ann Oncol; 1992 Sep; 3 Suppl 4():21-3. PubMed ID: 1450076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.